COVID-19 (SARS-CoV-2 Infection) Treatment
Covered by Aetna in California

Nirmatrelvir 300mg + ritonavir 100mg (Paxlovid) orally twice daily × 5 days — first-line antiviral for adults and pediatric patients ≥12 years weighing ≥40 kg with mild-to-moderate COVID-19 and ≥1 risk factor for severe disease. Must initiate within 5 days of symptom onset. Renal dose adjustment required: nirmatrelvir 150mg (one tablet) + ritonavir 100mg if eGFR 30–59 mL/min/1.73m²; contraindicated if eGFR <30. Drug-drug interactions are a significant prescribing consideration — ritonavir is a potent CYP3A4 inhibitor; statins, immunosuppressants, and certain antiarrhythmics may require temporary discontinuation.

Remdesivir (Veklury) IV — 3-day outpatient infusion for high-risk patients with Paxlovid contraindications (requires in-person infusion center referral). Molnupiravir (Lagevrio) 800mg orally twice daily × 5 days — alternative for adults only when neither Paxlovid nor remdesivir is feasible; NOT for use in pregnancy or those who may become pregnant. Supportive care: acetaminophen or ibuprofen for fever/myalgia, adequate hydration; pulse oximetry monitoring for high-risk patients (SpO2 ≤94% threshold for ER referral).

Yes — Paxlovid is covered without prior authorization under Aetna CA plans per Aetna's urgently-needed-services policy for COVID-19 therapeutics. Brand-name Paxlovid cost-sharing varies by plan tier; generic formulations may be available at Tier 1 pricing. Patient assistance programs (PAP) are available through Pfizer for underinsured and uninsured patients. No co-pay waiver exists post-PHE (public health emergency ended May 2023), so standard pharmacy cost-sharing applies.

Paxlovid eligibility per CDC/NIH guidelines requires: positive COVID-19 test (NAAT or antigen), mild-to-moderate disease (not requiring hospitalization or supplemental oxygen), and ≥1 high-risk criterion. High-risk criteria include age ≥50, obesity (BMI ≥25 for some populations), diabetes, heart disease, CKD, immunocompromise, unvaccinated status, or any condition on the NIH COVID treatment guidelines high-risk list. Patients with no risk factors and no comorbidities are managed with supportive care and do not require Paxlovid. COVID rebound (symptom recurrence 3–7 days after recovery) is a well-documented phenomenon; per CDC guidance, rebound symptoms are typically mild and self-limited and do NOT represent treatment failure or an indication for a second Paxlovid course. A second course is not currently recommended by CDC or NIH guidelines.

Yes. Aetna California covers Paxlovid (nirmatrelvir-ritonavir) under the pharmacy benefit for eligible members. Per Aetna's published clinical policy and member guidance, COVID-19 therapeutics — including Paxlovid — are covered without prior authorization, and COVID-19 treatment is designated an urgently needed service. The end of the federal PHE in May 2023 changed the government-provided free-drug program, so you now pay your standard pharmacy cost-sharing (copay or coinsurance) rather than receiving it at no cost. Your actual out-of-pocket cost depends on your specific Aetna CA plan tier; contact the number on your member ID card or check the Aetna formulary portal for your plan's current Paxlovid cost-sharing.

COVID rebound is a well-documented and expected phenomenon — it occurs in some patients whether or not they took Paxlovid, and it is not a sign that the first treatment failed. Per CDC guidance, rebound symptoms are typically mild and resolve within a few days. Current CDC and NIH treatment guidelines do NOT recommend a second course of Paxlovid for COVID rebound. You should isolate again per current CDC isolation guidance during the rebound period. Seek medical attention — including ER evaluation — only if you develop new oxygen desaturation (SpO2 ≤94%), significant chest pain, worsening dyspnea, or altered mental status. Dr. Bhavsar provides rebound counseling at every Paxlovid prescription so patients know what to expect.

Many patients on statins can still receive Paxlovid, but the drug-drug interaction requires clinical assessment. Ritonavir (the pharmacokinetic booster in Paxlovid) is a strong CYP3A4 inhibitor that dramatically increases levels of most statins — rosuvastatin and pravastatin are relatively safer alternatives. For patients on simvastatin, lovastatin, or atorvastatin, the standard approach is to temporarily hold the statin during the 5-day Paxlovid course and for 2–3 days after the last dose. Dr. Bhavsar reviews your full medication list during the visit and provides specific guidance on which medications to hold, adjust, or substitute. Patients on highly complex medication regimens (e.g., multiple antiretrovirals, immunosuppressants, certain antiarrhythmics) may be referred to in-person care or clinical pharmacy consultation.

TeleDirectMD offers same-day video visits 7 days a week, including weekends. Because Paxlovid must be started within 5 days of symptom onset to be effective, speed matters — testing positive on a Saturday and waiting until Monday for a clinic appointment wastes a critical day of the treatment window. After your visit with Dr. Bhavsar, the prescription is sent electronically to your preferred pharmacy. Most major California pharmacies (CVS, Walgreens, Rite Aid, Walmart, Costco) stock Paxlovid. For after-hours needs, 24-hour pharmacies in the Los Angeles, San Francisco Bay Area, San Diego, and Sacramento metro areas can fill the prescription the same day.

Yes. Aetna commercial plans cover telehealth visits for COVID-19 (SARS-CoV-2 Infection) in California. TeleDirectMD (Dr. Parth Bhavsar, MD, NPI: 1104323203) is an in-network telehealth provider with Aetna in California. Your standard Aetna telehealth copay applies — typically $10–$40 for most commercial plans. If clinically appropriate, your prescription is sent to your California pharmacy immediately after your visit.

Most Aetna commercial plans in California have telehealth copays of $10–$40. Often $0–$20 for employer plans. Your exact cost depends on your specific plan and whether your deductible has been met. Log into your Aetna member portal or call the member services number on your card to verify your telehealth copay before your covid-19 treatment visit. Self-pay is always available for a flat $49 if you prefer to skip insurance.

If your specific Aetna plan is not in-network with TeleDirectMD in California, or if your deductible has not yet been met, you can book as a self-pay patient for a flat $49 fee — same physician, same quality of care, no insurance needed. You may also be eligible to submit an out-of-network claim to Aetna for partial reimbursement depending on your plan's out-of-network benefit.

TeleDirectMD typically offers same-day and next-day video visits. Book at teledirectmd.com/book-online and select a time that works for you. Most patients are seen within a few hours of booking during business hours. Your covid-19 treatment symptoms are evaluated by Dr. Bhavsar, MD — not a nurse practitioner or PA — ensuring you receive a board-certified clinical assessment.

Yes. TeleDirectMD is operated by Dr. Parth Bhavsar, MD (NPI: 1104323203), a board-certified Family Medicine physician. TeleDirectMD is LegitScript certified, HIPAA compliant, and is contracted as an in-network telehealth provider with Aetna in California. Claims are billed using standard CPT codes (99213/99214) and submitted electronically to Aetna.

Yes. Telehealth visits with a licensed physician are qualified medical expenses eligible for FSA (Flexible Spending Account) and HSA (Health Savings Account) payment. If your Aetna plan applies your deductible first, your FSA or HSA card can be used to pay your portion. The $49 self-pay option is also FSA/HSA eligible.